153436-54-5
153436-54-5 结构式
基本信息
N-(3-溴苯基)-6,7-二甲氧基喹唑啉-4-胺
PD153035
ZM 252868
AG 1517
4-[(3-溴苯基)氨基]-6,7-二甲氧基喹唑啉盐酸盐
Zinc00600292
PD 153035(AG-1517)
PD 153035 HYDROCHLORIDE
4-(3-Bromo-benzyl)-6,7-dimethoxy-quinazoline
4-(3-Bromphenylamino)-6,7-dimethylquinazoline
4-(3-Bromphenylamino)-6,7-bis(methoxy)quinazoline
N-(3-bromophenyl)-6,7-dimethoxyquinazolin-4-amine
4-Quinazolinamine, N-(3-bromphenyl)-6,7-dimethoxy-
4-[(3-BROMOPHENYL)AMINO]-6,7-DIMETHOXYQUINAZOLINE HYDROCHLORIDE
物理化学性质
制备方法
591-19-5
13790-39-1
153436-54-5
通用方法：将4-氯-6,7-二甲氧基喹唑啉（1 mmol）溶于回流的2-丙醇（20 mL）中，逐滴加入间溴苯胺（1 mmol）。将反应混合物回流3-4小时，通过TLC监测反应进度直至完成。反应完成后，滤出沉淀，依次用2-丙醇（10 mL）和乙醚（10 mL）洗涤。若未观察到沉淀形成，则在减压条件下移除溶剂，获得固体产物。最终产物通过75%乙醇溶液进行重结晶纯化。
参考文献：
[1] Tetrahedron, 2010, vol. 66, # 4, p. 962 - 968
[2] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 24, p. 7858 - 7873
[3] Journal of Labelled Compounds and Radiopharmaceuticals, 1998, vol. 41, # 7, p. 623 - 629
[4] Bioorganic and Medicinal Chemistry Letters, 2007, vol. 17, # 22, p. 6373 - 6377
[5] Bioorganic and Medicinal Chemistry, 1996, vol. 4, # 8, p. 1203 - 1207
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/05/22 | HY-12013 | 4-[(3-溴苯基)氨基]-6,7-二甲氧基喹啉 PD153035 Hydrochloride | 153436-54-5 | 5mg | 309元 |
| 2025/05/22 | HY-12013 | 4-[(3-溴苯基)氨基]-6,7-二甲氧基喹啉 PD153035 Hydrochloride | 153436-54-5 | 10mg | 411元 |
| 2025/05/22 | HY-12013 | 4-[(3-溴苯基)氨基]-6,7-二甲氧基喹啉 PD153035 Hydrochloride | 153436-54-5 | 25 mg | 680元 |
常见问题列表
| Target | Value |
|
EGFR
(Cell-free assay) | 5.2 pM(Ki) |
PD153035 (SU 5271) inhibits EGF-stimulated receptor autophosphorylation in A431 human epidermoid carcinoma cells, with an IC 50 of 14 nM. PD153035 (SU 5271) has little effect on PDGFR, FGFR, CSF-1 receptor, the insulin receptor, or on src tyrosine kinases at concentrations as high as 50 μM. PD153035 (SU 5271) rapidly suppresses autophosphorylation of the EGF receptor at low nanomolar concentrations in fibroblasts or in human epidermoid carcinoma cells and selectively blocks EGF-mediated cellular processes including mitogenesis, early gene expression, and oncogenic transformation. PD153035 (SU 5271) causes a dose-dependent growth inhibition of EGF receptor-positive cell lines, beginning at less than micromolar concentrations, and the IC 50 is less than 1 pM in most cases.
PD153035 (SU 5271) levels in the plasma and tumor rise to 50 and 22 μM within 15 minutes following a single i.p. dose of 80 mg/kg. While the plasma levels of PD153035 (SU 5271) falls below 1 μM by 3 hours, in the tumors it remains at micromolar concentrations for at least 12 hours. The tyrosine phosphorylation of the EGF receptor is rapidly suppressed by 80-90% in the tumors.